# OnCo record aprea-therapeutics (company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/companies/aprea-therapeutics/>
  a schema:Organization ;
  onco:kind "company" ;
  schema:identifier "aprea-therapeutics" ;
  schema:name "Aprea Therapeutics"@en ;
  schema:alternateName "Aprea Therapeutics, Inc."@en, "Aprea"@en ;
  schema:description "Aprea developed eprenetapopt, a drug meant to restore the function of mutant p53, which failed its phase 3 trial in TP53-mutant myelodysplastic syndromes in 2020; the company now works on ATR and WEE1 inhibitors."@en ;
  schema:url <https://onco.cc/companies/aprea-therapeutics/>, <https://aprea.com> ;
  schema:dateModified "2026-09-11"^^xsd:date ;
  schema:citation <https://aprea.com>, <https://clinicaltrials.gov/search?lead=Aprea%20Therapeutics> ;
  onco:tag "ctgov-sponsor" ;
  schema:addressCountry "US" ;
  onco:cancers <https://onco.cc/cancers/mds/>, <https://onco.cc/cancers/aml/> ;
  onco:sections <https://onco.cc/fronts/targeted-therapy/> ;
  onco:targets <https://onco.cc/targets/tp53/>, <https://onco.cc/targets/atr/> ;
  onco:drugs <https://onco.cc/drugs/eprenetapopt/> .